ImmunityBio, Inc. (IBRX) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, ImmunityBio reported revenue of $113.3M, up 668.3% from $14.7M the year before. Net income was -$351.4M (a -310.2% net margin), or -$0.38 per diluted share. Gross margin was 99.3% and operating margin was -226.0%. Operating activities generated -$304.9M of cash, leaving -$308.7M of free cash flow. At fiscal year end, ImmunityBio held $501.9M in total assets against $1.00B in total liabilities, including $88.3M of cash and equivalents.
Open the full interactive ImmunityBio financials → Quarterly statements, key ratios, valuation history and price charts.
ImmunityBio Key Stats
| Share Price | $9.80 |
|---|---|
| Market Cap | $10.29B |
| Revenue YoY Growth | +668.3% |
| 52-Week Range | $1.98 – $11.55 |
| Shares Outstanding | 1.05 billion (basic, 2026 Q2) |
ImmunityBio Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $111,000 | $934,000 | $240,000 | $622,000 | $14.7M | $113.3M |
| Cost of Goods Sold | — | — | — | — | $0 | $753,000 |
| Gross Profit | — | — | — | — | $14.7M | $112.5M |
| Operating Income | -$91.6M | -$330.3M | -$351.3M | -$362.2M | -$344.2M | -$256.0M |
| Pre-Tax Income | -$92.4M | -$349.8M | -$417.3M | -$583.9M | -$413.6M | -$351.6M |
| Income Tax | $5,000 | $9,000 | $34,000 | -$40,000 | $0 | -$135,000 |
| Net Income | -$92.4M | -$346.8M | -$416.6M | -$583.2M | -$413.6M | -$351.4M |
| Diluted EPS | -$0.89 | -$0.89 | -$1.04 | -$1.15 | -$0.62 | -$0.38 |
ImmunityBio Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $32.1M | $38.3M | $44.2M | $51.2M |
| Net Income | -$67.3M | -$61.9M | -$632.8M | -$230.4M |
| Diluted EPS | -$0.07 | -$0.07 | -$0.62 | -$0.22 |
ImmunityBio Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.4M | $181.1M | $104.6M | $265.5M | $143.4M | $88.3M |
| Current Assets | $75.5M | $334.3M | $140.6M | $294.1M | $184.6M | $314.9M |
| Total Assets | $151.9M | $468.9M | $362.4M | $504.5M | $382.9M | $501.9M |
| Current Liabilities | $24.7M | $369.0M | $500.9M | $58.3M | $54.9M | $61.8M |
| Total Long-Term Debt | — | — | — | $732.4M | $284.4M | $324.6M |
| Total Liabilities | $34.5M | $712.8M | $812.2M | $1.09B | $871.1M | $1.00B |
| Shareholders' Equity | $117.4M | -$242.2M | -$447.3M | -$587.0M | -$489.1M | -$500.5M |
ImmunityBio Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$70.5M | -$274.4M | -$337.5M | -$366.8M | -$391.2M | -$304.9M |
| Cash From Investing | -$20.6M | -$84.9M | $27.3M | -$30.5M | -$12.2M | -$149.8M |
| Cash From Financing | $87.0M | $505.4M | $233.6M | $558.3M | $281.6M | $400.2M |
| Free Cash Flow | -$73.1M | -$308.0M | -$415.7M | -$397.4M | -$398.1M | -$308.7M |
Figures from ImmunityBio's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full ImmunityBio financials page for every line item.
ImmunityBio Company Profile
| Ticker | IBRX |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001326110 |
Frequently Asked Questions
What was ImmunityBio's revenue in fiscal 2025?
ImmunityBio (IBRX) reported revenue of $113.3M for fiscal 2025.
What is ImmunityBio's annual revenue history?
ImmunityBio's annual revenue by fiscal year: 2020: $111,000; 2021: $934,000; 2022: $240,000; 2023: $622,000; 2024: $14.7M; 2025: $113.3M.
What was ImmunityBio's net income in fiscal 2025?
ImmunityBio reported net income of -$351.4M for fiscal 2025.
What was ImmunityBio's earnings per share (EPS) in fiscal 2025?
ImmunityBio's diluted EPS was -$0.38 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did ImmunityBio generate in fiscal 2025?
ImmunityBio generated -$308.7M of free cash flow in fiscal 2025.
What was ImmunityBio's revenue last quarter?
In its most recent reported quarter (2026 Q2), ImmunityBio reported revenue of $51.2M.
How much debt does ImmunityBio have?
ImmunityBio reported $324.6M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of ImmunityBio are outstanding?
ImmunityBio reported a weighted average of 1.05 billion basic shares outstanding in 2026 Q2.
What is ImmunityBio's market cap?
Based on its latest closing price, ImmunityBio (IBRX) has a market capitalization of about $10.29B.
When does ImmunityBio's fiscal year end?
ImmunityBio's fiscal year end, as registered with the SEC, is December 31.
Where is ImmunityBio headquartered?
ImmunityBio lists its business address in San Diego, California in its SEC filings.
ImmunityBio Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →